St. Louis–Based Remvia Receives FDA 510(k) Clearance for a Patented, Non-Tooth-Supported Device for Clenching and Grinding
St. Louis, MO – February 3, 2026 — Remvia LLC today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for Remvia NightGuard, an oral medical device indicated for protection against teeth grinding (bruxism) and jaw clenching.
Remvia is an oral device designed to be supported along the inner cheek rather than the teeth, addressing nighttime teeth grinding and jaw clenching without relying on dentition-based retention.
The FDA clearance supports Remvia’s initial clinical rollout beginning in early February 2026, marking a key milestone as the company prepares to make the device available through clinical channels.
The announcement follows the recent issuance of U.S. Patent No. 12,491,106, granted on December 9, 2025, which covers apparatus and methods for the treatment of bruxism and provides intellectual property protection for the core design underlying Remvia NightGuard.
“Receiving FDA clearance is an important step forward for Remvia,” said Andrea Morris, DDS, Founder and CEO of Remvia. “This milestone reflects years of careful design and clinical consideration and allows us to move into an initial clinical rollout while continuing to build responsibly.”
Remvia has been selected as part of the 2025 Arch Grants cohort, highlighting the region’s backing of the company’s ongoing growth and progress in St. Louis. “Remvia represents the kind of disciplined, founder-led innovation we aim to support—companies that are advancing meaningful solutions while building for long-term impact,” said Gabe Angieri, Executive Director of Arch Grants.
“This is an exciting moment for Andrea and her business! We’re proud to have witnessed Andrea move from early concept designs and developing her prototypes on our 3-D printers, to having strategic meetings with her partners and developing a plan of success, receiving an Arch Grant, going through the patent approval process, and finally bringing her product to market. Andrea’s revolutionary product is truly an exciting example of the innovation and success that’s happening not only at T-REX, but the St. Louis region as whole.” -Jesse A. Winters, CEO of T-Rex.
About Remvia
Remvia was founded by Andrea Morris, DDS, and was joined by co-founder Nephi Zufelt, who leads engineering and regulatory development, and works closely with Andrew Bruening, Chief Innovation Officer, with expertise in digital design and a co-owner of Hilltown Dental. Remvia is a St. Louis–based medical device company focused on improving care for patients affected by nighttime teeth grinding and jaw clenching.
